Literature DB >> 28444390

Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells.

Monday O Ogese1, Lee Faulkner2, Roz E Jenkins2, Neil S French2, Ian M Copple2, Daniel J Antoine2, Mohamed Elmasry3,4, Hasan Malik5, Christopher E Goldring2, Brian Kevin Park2, Catherine J Betts1, Dean J Naisbitt2.   

Abstract

It is now apparent that antigen-specific T-cells are activated in certain patients with drug-induced liver injury (DILI). Since cross-talk between hepatocytes and immune cells is likely to be critical in determining the outcome of drug exposure, the aim of this study was to profile the signals released by drug-treated hepatocytes and to characterize the impact of these molecules on dendritic cells. Human hepatocytes were exposed to 3 drugs (flucloxacillin, amoxicillin, and isoniazid) associated with DILI potentially mediated by the adaptive immune system as drug-specific T-cells have been isolated from DILI patients, and the metabolite nitroso-sulfamethoxazole (SMX-NO). Hepatocyte toxicity, cytokine release and activation of oxidative stress pathways were measured. Supernatants were transferred to monocyte-derived dendritic cells and cell phenotype and function were assessed. High-mobility group box 1 protein (HMGB1) and lactate dehydrogenase release as well as adenosine triphosphate depletion occurred in a drug-, time-, and concentration-dependent manner with SMX-NO and flucloxacillin, whereas isoniazid and amoxicillin were nontoxic. Furthermore, drug-induced activation of nuclear factor (erythroid-derived 2)-like 2 marker genes was observed when hepatocytes were exposed to test drugs. The disulfide isoform of HMGB1 stimulated dendritic cell cytokine release and enhanced the priming of naive T-cells. Incubation of dendritic cells with supernatant from drug-treated hepatocytes resulted in 2 distinct cytokine profiles. SMX-NO/flucloxacillin stimulated secretion of TNF-α, IL-6, IL-1α, and IL-1-β. Isoniazid which did not induce significant hepatocyte toxicity, compared with SMX-NO and flucloxacillin, stimulated the release of a panel of cytokines including the above and IFN-γ, IL-12, IL-17A, IP-10, and IL-10. Collectively, our study identifies drug-specific signaling pathways between hepatocytes and immune cells that could influence whether drug exposure will result in an immune response and tissue injury.
© The Author 2017. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  drug hypersensitivity; human; immune system

Mesh:

Substances:

Year:  2017        PMID: 28444390     DOI: 10.1093/toxsci/kfx069

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  12 in total

Review 1.  Biomarkers of adverse drug reactions.

Authors:  Daniel F Carr; Munir Pirmohamed
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-26

Review 2.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

Review 3.  Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery.

Authors:  Dominic P Williams
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

4.  Hepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury.

Authors:  Natalie S Holman; Rachel J Church; Manisha Nautiyal; Kelly A Rose; Sarah E Thacker; Monicah A Otieno; Kristina K Wolf; Edward LeCluyse; Paul B Watkins; Merrie Mosedale
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

Review 5.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

Review 6.  Drug-Induced Liver Injury: Highlights of the Recent Literature.

Authors:  Mark Real; Michele S Barnhill; Cory Higley; Jessica Rosenberg; James H Lewis
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

7.  Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.

Authors:  Kristina M Brooks; Jomy M George; Alice K Pau; Adam Rupert; Carolina Mehaffy; Prithwiraj De; Karen M Dobos; Anela Kellogg; Mary McLaughlin; Maryellen McManus; Raul M Alfaro; Colleen Hadigan; Joseph A Kovacs; Parag Kumar
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

8.  "Thinking" vs. "Talking": Differential Autocrine Inflammatory Networks in Isolated Primary Hepatic Stellate Cells and Hepatocytes under Hypoxic Stress.

Authors:  Yoram Vodovotz; Richard L Simmons; Chandrashekhar R Gandhi; Derek Barclay; Bahiyyah S Jefferson; Chao Huang; Rami Namas; Fayten El-Dehaibi; Qi Mi; Timothy R Billiar; Ruben Zamora
Journal:  Front Physiol       Date:  2017-12-22       Impact factor: 4.566

9.  Exosomal Transport of Hepatocyte-Derived Drug-Modified Proteins to the Immune System.

Authors:  Monday O Ogese; Rosalind E Jenkins; Kareena Adair; Arun Tailor; Xiaoli Meng; Lee Faulkner; Bright O Enyindah; Amy Schofield; Rafael Diaz-Nieto; Lorenzo Ressel; Gina L Eagle; Neil R Kitteringham; Chris E Goldring; B Kevin Park; Dean J Naisbitt; Catherine Betts
Journal:  Hepatology       Date:  2019-06-29       Impact factor: 17.425

Review 10.  High-Mobility Group Box-1 and Liver Disease.

Authors:  Harriet Gaskell; Xiaodong Ge; Natalia Nieto
Journal:  Hepatol Commun       Date:  2018-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.